Athabasca Oil, Cenovus Energy Create Duvernay Energy
By Stephen Nakrosis
Athabasca Oil said Tuesday it would work with Cenovus Energy to create Duvernay Energy, a standalone company with assets in Alberta's Kaybob Duvernay play.
The deal would see Athabasca own a 70% equity interest in the new company, while Cenovus would own the remaining 30%. Athabasca said it would manage Duvernay Energy as part of a management and operating services agreement.
Robert Broen, president and chief executive officer of Athabasca Oil, will assume the role of chairman, president and CEO of Duvernay Energy. Duvernay's board will include three members nominated by Athabasca and one member nominated by Cenovus, Athabasca said.
The new company will be debt free and seeded with $40 million cash and a $50 million credit facility, according to Athabasca.
The deal will have an effective date of Jan. 1, 2024, and is expected to close in the first quarter of next year.
Duvernay Energy will have exposure to about 200,000 gross acres with around 500 gross future well locations, Athabasca said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 19, 2023 17:43 ET (22:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks